UPDATE: Regeneron Pharma (REGN) Easily Tops Q4 EPS Views; Guides FY14 EYLEA Sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks hit by tech slide; yen flails at intervention zone
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
BofA/Merrill Lynch Reinstated Regeneron Pharma (REGN) at Buy
February 12, 2014 6:49 AM ESTBofA/Merrill Lynch reinstated coverage on Regeneron Pharma (NASDAQ: REGN) with a Buy rating and price target of $387.00.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more... More
Regeneron Pharma (REGN) PT Raised to $410 at Deutsche Bank
February 11, 2014 2:32 PM ESTDeutsche Bank reiterated a Buy rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $410.00 (from $375.00).
Analyst Robyn Karnauskas said, "The key takeaway from REGN Q4'13 call was that the co expects to see tax benefit from Ireland... More
Regeneron Pharma (REGN) May Have Upside From Taxes - Analyst
February 11, 2014 10:36 AM ESTDeutsche Bank maintained a Buy rating on Regeneron Pharma (NASDAQ: REGN) with a price target of $375.00. The company earlier reported Q4 results. Analyst Robyn Karnauskas commented on potential upside from taxes.
"REGN just announced they are building a manufacturing facility in... More
